ANP meeting with US FDA granted for ATL1102 in DMD
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Quarterly Update and Appendix 4C
- Annual General Meeting Chairmans Address
- EC grants Orphan Drug Designation for ATL1102 in DMD
- Receipt of R&D Tax Incentive payment
- ANP raises A$7.3 million from Oversubscribed Placement
Later from Percheron Therapeutics
- Half Yearly Report and Half Year Accounts
- ATL1102 DMD Paediatric Investigation Plan submitted to EMA
- US FDA Type C Meeting for ATL1102 in DMD
- Manufacture of ATL1102 clinical supplies for Phase IIb trial
- US FDA Feedback on Type C Meeting for ATL1102 in the US
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics